Optic Neuritis

Educational Objectives

The goal of this program is to improve management of optic neuritis and its variants. After hearing and assimilating this program, the clinician will be better able to:

1. Explain imaging features requiring urgent hospitalization and intravenous methylprednisolone therapy.
2. Identify clinical and demographic red flags indicating atypical optic neuritis.
3. Avoid oral corticosteroids in conventional dosing for optic neuritis management.

Summary

Paradigm shift in optic neuritis management: traditional teaching from the Optic Neuritis Treatment Trial no longer applies universally; historical approach suggested magnetic resonance imaging (MRI) was only needed to assess multiple sclerosis (MS) risk, intravenous (IV) steroids merely hastened recovery without changing outcomes, and laboratory testing was unnecessary; modern understanding requires MRI to evaluate enhancement patterns, recognition that some forms require aggressive treatment to prevent permanent vision loss and paralysis, and mandatory antibody testing before steroid administration; the classification framework now includes good (idiopathic optic neuritis), bad (myelin oligodendrocytic glycoprotein [MOG]), and ugly (neuromyelitis optica [NMO]) categories, each with distinct prognoses and treatment implications

Clinical red flags for atypical optic neuritis: classic presentation remains 20-yr-old White woman with acute unilateral vision loss, relative afferent pupillary defect (RAPD), and normal fundus; deviations from this pattern warrant heightened suspicion for MOG or NMO; patients >40 yr or <10 yr at greater risk; risk factors for NMO include Black race, Afro-Caribbean, Asian descent, or equatorial region origin; clinical features for atypical optic neuritis include bilateral involvement (simultaneous or sequential), significant disc swelling, absence of pain, or severe pain; recovery pattern characterized by failure to improve or recurrent episodes; any combination of atypical features should prompt immediate consideration of antibody-mediated disease

Geographic and demographic patterns: MS demonstrates clear latitude gradient with highest incidence in northern hemisphere and corresponding southern latitudes, rare in equatorial regions; NMO shows opposite pattern with higher prevalence in equatorial regions and among populations of African, Afro-Caribbean, and Asian descent; clinicians practicing in areas with diverse patient populations or seeing patients from equatorial regions should maintain high index of suspicion for NMO; presence of other autoimmune conditions increases NMO likelihood

MRI protocol requirements: standard imaging for optic neuropathy must include head, orbits, gadolinium, and fat saturation; recite as single phrase ("MR head orbit gadolinium fatsat"); inadequate protocols missing gadolinium, fat saturation, or orbital sequences account for majority of missed diagnoses; fat saturation critical because unsuppressed orbital fat creates "polar bear in a snowstorm" effect obscuring enhancement; 95% of true optic neuritis cases show enhancement, making absence of enhancement on adequate study highly suspicious for alternative diagnosis; enhancement patterns guide classification; traditional optic neuritis characterized by short intraorbital segment, mid-orbital location, ipsilateral to affected eye; MOG characterized by enhancement extending into sheath and orbital fat; NMO characterized by longitudinally extensive enhancement (>50% of nerve length), bilateral enhancement, or chiasmal involvement; radiologists must specify enhancement length, location (nerve vs sheath vs fat), and laterality rather than simply reporting "optic neuritis"

Antibody testing protocols: 2 essential tests required for all atypical optic neuritis, including MOG antibody and NMO antibody (aquaporin-4); cell-based assay (CBA) significantly more specific than enzyme-linked immunosorbent assay (ELISA) and mandatory for negative results; tissue-based assays insufficient; critical timing requirement: must order tests before steroid administration as steroids cause antibody levels to become undetectable; seronegative status has major treatment implications as no currently approved NMO therapies have indication for seronegative disease; failure to obtain pre-steroid antibody testing represents medical error that eliminates treatment options; test turnaround ≈2 wk; immediate Monday action items include verifying institutional laboratory uses cell-based assay and establishing ordering protocols

Indications for antibody testing: test all patients with bilateral optic neuritis (simultaneous or sequential), recurrent optic neuritis, optic neuritis with normal brain MRI (absence of MS lesions), optic neuritis in atypical demographics, disc swelling, absence of pain or severe pain, poor recovery, transverse myelitis at any time, unexplained nausea, vomiting, intractable hiccups in preceding 3 mo, diplopia with optic neuritis, or nystagmus; additionally test retrospectively in patients with previously diagnosed optic neuritis who failed to recover vision; essentially, lower threshold for testing than for treating given devastating consequences of missed diagnosis

NMO pathophysiology and natural history: aquaporin-4 antibody targets water channels on astrocytes; antibody binding causes astrocyte death with permanent neural damage; characterized by "one and done" attack pattern rather than relapsing-remitting course of MS; single attack often causes irreversible disability; clinical course shows rapid, steep decline rather than fluctuating pattern; core clinical criteria include optic neuritis, myelitis, and area postrema syndrome (unexplained nausea, vomiting, intractable hiccups); additional manifestations include acute brainstem syndromes, narcolepsy, diplopia, and ocular motor dysfunction; NMO-rich areas span from chiasm around cerebral aqueduct to area postrema and into spinal cord; any chiasmal involvement beyond isolated optic nerve indicates NMO; myelitis defined as 3 contiguous spinal segments on MRI

NMO outcomes and urgency: 10% mortality rate; 40% blind in ≥1 eye after single attack; 78% have residual deficit after attack; 25% require gait assistance; 80% develop transverse myelitis within 2 yr if seropositive and untreated; 50% paralyzed within 10 mo of initial presentation; average time to diagnosis 3 yr, average time to treatment 6 mo; 42% misdiagnosed as MS by experienced ophthalmologists and neurologists; ophthalmologist often sole clinician seeing patient at time zero before myelitis develops, creating unique opportunity and responsibility for diagnosis; at initial optic neuritis presentation, patient faces 10% risk for death and 80% risk for paralysis within 2 yr if NMO goes unrecognized; permanent paraplegia from myelitis attack represents preventable outcome through early diagnosis and treatment

Oral corticosteroid contraindication: Optic Neuritis Treatment Trial demonstrates oral prednisone in conventional dosing doubles recurrence rate compared with placebo; patients receiving oral steroids (methylprednisolone dose pack) have worse outcomes than those receiving no treatment; "poking the bear" analogy reflects how oral steroids paradoxically worsen disease course; methylprednisolone dose pack appropriate only for poison ivy, has no role in neuro-ophthalmology; despite clear evidence, 20% of ophthalmologists continue prescribing oral steroids for optic neuritis; absolute contraindication applies to all optic neuritis variants

IV methylprednisolone protocols: traditional optic neuritis (MS-associated) shows equivalent long-term outcomes with IV steroids, oral steroids, or placebo in original trial, with IV route only hastening recovery; however, MOG and NMO require IV methylprednisolone to prevent permanent blindness; original treatment window of 8 days from Optic Neuritis Treatment Trial no longer applicable; current standard requires hospital admission for immediate IV methylprednisolone regardless of day or time; day 3 assessment critical; if no improvement by day 3, proceed to plasma exchange; given 2-wk turnaround for antibody results and inability to distinguish NMO/MOG from traditional optic neuritis clinically at presentation, practical approach involves admitting all optic neuritis patients for IV steroids and antibody testing; exception: clear MS diagnosis with typical demographic, short-segment intraorbital enhancement on MRI, and white matter lesions consistent with MS can be managed with outpatient IV steroids or observation

When to hospitalize: current practice requires hospital admission for nearly all optic neuritis presentations given inability to exclude NMO or MOG at initial evaluation; optic neuritis no longer considered condition appropriate for outpatient workup and Monday MRI; only patients with unequivocal MS diagnosis (20-yr-old White woman, acute unilateral vision loss, RAPD, normal fundus, MRI showing white matter lesions, short intraorbital segment of enhancement) can potentially be managed outpatient; all atypical features mandate admission; normal brain MRI particularly concerning as may indicate NMO rather than reassuring finding; admission allows immediate IV methylprednisolone, MRI within 1 to 2 days, pre-treatment antibody testing, and rapid escalation to plasma exchange if needed

Multidisciplinary collaboration requirements: ophthalmologists cannot manage NMO or MOG in isolation; essential to establish relationship with neurology colleague willing to admit optic neuritis patients urgently regardless of day or time, administer IV methylprednisolone, arrange plasma exchange if needed, and provide long-term NMO and MOG management; ophthalmology laboratories must verify use of cell-based assay for antibody testing; radiology departments require education on reporting requirements (enhancement length, nerve vs sheath vs fat involvement, bilateral vs unilateral) rather than generic "optic neuritis" interpretation; institutional protocols should facilitate pre-steroid antibody ordering and rapid MRI access; team approach essential as ophthalmologist lacks expertise in plasma exchange ordering and long-term immunosuppression management while serving as sole clinician recognizing disease at presentation

Practice change imperatives: verify institutional laboratory uses cell-based assay for MOG and NMO antibody testing; establish neurology colleague relationship for urgent admissions; educate radiology on enhancement pattern reporting requirements; create admission protocols ensuring antibody tests ordered before steroids; eliminate oral corticosteroids from optic neuritis management; lower threshold for hospitalization given high stakes of missed NMO or MOG diagnosis; recognize that patient presenting with isolated optic neuritis faces potential timeline to paralysis measured in months, with ophthalmologist representing only opportunity for intervention before irreversible myelitis; missed diagnosis in alternate universe where provider lacks current knowledge results in preventable blindness, paralysis, and death

Readings

Disclosures

For this program, the following relevant financial relationships were disclosed and mitigated to ensure that no commercial bias has been inserted into this content: Dr. Lee has a financial relationship with Amgen, Argenyx, AstraZeneca, Alexion, Bristol Myers Squibb, Catalyst, Dompe, Viridian, and Stoke. Members of the planning committee reported nothing relevant to disclose.

Acknowledgements

Dr. Lee was recorded at the The 24th Annual Downeast Ophthalmology Symposium, held on September 19-21, 2025, in Bar Harbor, ME, and presented by The Maine Society of Eye Physicians and Surgeons. For information about upcoming CME activities from this presenter, please visit https://maineeyemds.com. Audio Digest thanks Dr. Lee and The Maine Society of Eye Physicians and Surgeons for their cooperation in the production of this program.

CME/CE INFO

Accreditation:

Lecture ID:

OP640701

Qualifies for:

Expiration:

This CME course qualifies for AMA PRA Category 1 Credits™ for 3 years from the date of publication.

Instructions:

To earn CME/CE credit for this course, you must complete all the following components in the order recommended: (1) Review introductory course content, including Educational Objectives and Faculty/Planner Disclosures; (2) Listen to the audio program and review accompanying learning materials; (3) Complete posttest (only after completing Step 2) and earn a passing score of at least 80%. Taking the course Pretest and completing the Evaluation Survey are strongly recommended (but not mandatory) components of completing this CME/CE course.

Estimated time to complete this CME/CE course:

Approximately 2x the length of the recorded lecture to account for time spent studying accompanying learning materials and completing tests.